

APPENDIX: CONDITIONS OF THE SHARE ISSUE

Pursuant to authorization given by the General Meeting held on 13 April 2011 Biohit Oyj's ("Company") Board of Directors has decided to issue 677 966 new B-shares ("Shares") through a directed share issue to Sartorius Lab Holding GmbH ("Sartorius") in accordance with the following conditions:

1. Subscription of Shares

The number of Shares issued is 677 966 shares. The Shares are new.

The issued Shares shall be subscribed in full and no partial subscription is allowed.

The Shares have been issued in deviation from the pre-emptive subscription right of the shareholders.

The Board of Directors approves all the subscriptions made in accordance with these terms and conditions.

2. Subscription Price and Entry on the Balance Sheet

The subscription price is 2.95 euros per Share ("Subscription Price"). The Subscription Price is over 20 % higher than the three-month volume weighted average price of the Company's B shares at NASDAQ OMX Helsinki preceding the date of this share issue. 0.17 euros of the Subscription Price is credited to Company's share capital and 2.78 euros to the reserve for invested unrestricted equity of the Company.

3. Date and Place for Subscription

The date for the subscription is 19 August 2011. The subscription is carried out by delivering an executed subscription list to Board of Directors of the Company.

4. Payment Terms

The subscription price shall be paid on 19 August 2011 to the bank account notified by the Company.

5. Right to Dividends and Other Rights

The Shares are entitled to dividend and carry all other shareholder rights in the Company as of the registration of the Shares with the Finnish Trade Register unless otherwise provided by the Limited Liability Companies Act. The registration takes place on or about 29 August 2011.

The Shares are issued as book-entry securities in book-entry system held by Euroclear Finland Oy.

6. Grounds for Deviating from Pre-emptive Subscription Right

The grounds for deviating from shareholders' pre-emptive subscription right are the objectives to strengthen the Company's capital structure and to support the Company's business and growth. In addition, the directed share issue is justified taking into consideration the low costs and quickness in execution compared to issue of shares under pre-emptive subscription right.

7. Listing of the Shares

The Company shall on or about 22 August 2011 submit an application with NASDAQ OMX Helsinki regarding the listing of the Shares as an additional lot of the listed B shares. The trading in the Shares is expected to commence on or about 30 August 2011.

8. Other Conditions

Board of Directors has the right to decide on other practical matters and arrangements related to Share issuance.

Laws of Finland shall be applied to the Shares.